Cargando…
A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
BACKGROUND: The MEK inhibitor, selumetinib, suppresses soft-tissue sarcoma (STS) cell proliferation in vitro. Mammalian target of rapamycin inhibitors possess modest activity against STS; however, resistance develops via MAPK pathway feedback activation. The combination of selumetinib and temsirolim...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430716/ https://www.ncbi.nlm.nih.gov/pubmed/25897676 http://dx.doi.org/10.1038/bjc.2015.126 |
_version_ | 1782371224900337664 |
---|---|
author | Eroglu, Z Tawbi, H A Hu, J Guan, M Frankel, P H Ruel, N H Wilczynski, S Christensen, S Gandara, D R Chow, W A |
author_facet | Eroglu, Z Tawbi, H A Hu, J Guan, M Frankel, P H Ruel, N H Wilczynski, S Christensen, S Gandara, D R Chow, W A |
author_sort | Eroglu, Z |
collection | PubMed |
description | BACKGROUND: The MEK inhibitor, selumetinib, suppresses soft-tissue sarcoma (STS) cell proliferation in vitro. Mammalian target of rapamycin inhibitors possess modest activity against STS; however, resistance develops via MAPK pathway feedback activation. The combination of selumetinib and temsirolimus synergistically inhibits STS cell line growth. Therefore, a randomized phase II trial of selumetinib vs selumetinib plus temsirolimus was conducted. METHODS: Seventy-one adults with advanced STS who received ⩽2 prior chemotherapeutics were randomized to selumetinib 75 mg p.o. bid and allowed to crossover upon progression, or to selumetinib 50 mg p.o. bid plus temsirolimus 20 mg i.v. weekly, with primary endpoint of progression-free survival (PFS). RESULTS: There was no difference in PFS between the two arms for the overall cohort (median 1.9 vs 2.1 months); an improved median PFS was observed in the combination arm (N=11) over single agent (N=10) in the prespecified leiomyosarcoma stratum (median 3.7 vs 1.8 months; P=0.01). Four-month PFS rate was 50% (95% confidence interval 0.19–0.81) with the combination vs 0% with selumetinib alone in the leiomyosarcoma cohort. Most common grade 3/4 adverse events with the combination were mucositis (29%), lymphopenia (26%), neutropenia and anaemia (20% each). CONCLUSIONS: While single-agent selumetinib has no significant activity in STS, the combination may be active for leiomyosarcomas. |
format | Online Article Text |
id | pubmed-4430716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-44307162015-05-21 A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas Eroglu, Z Tawbi, H A Hu, J Guan, M Frankel, P H Ruel, N H Wilczynski, S Christensen, S Gandara, D R Chow, W A Br J Cancer Clinical Study BACKGROUND: The MEK inhibitor, selumetinib, suppresses soft-tissue sarcoma (STS) cell proliferation in vitro. Mammalian target of rapamycin inhibitors possess modest activity against STS; however, resistance develops via MAPK pathway feedback activation. The combination of selumetinib and temsirolimus synergistically inhibits STS cell line growth. Therefore, a randomized phase II trial of selumetinib vs selumetinib plus temsirolimus was conducted. METHODS: Seventy-one adults with advanced STS who received ⩽2 prior chemotherapeutics were randomized to selumetinib 75 mg p.o. bid and allowed to crossover upon progression, or to selumetinib 50 mg p.o. bid plus temsirolimus 20 mg i.v. weekly, with primary endpoint of progression-free survival (PFS). RESULTS: There was no difference in PFS between the two arms for the overall cohort (median 1.9 vs 2.1 months); an improved median PFS was observed in the combination arm (N=11) over single agent (N=10) in the prespecified leiomyosarcoma stratum (median 3.7 vs 1.8 months; P=0.01). Four-month PFS rate was 50% (95% confidence interval 0.19–0.81) with the combination vs 0% with selumetinib alone in the leiomyosarcoma cohort. Most common grade 3/4 adverse events with the combination were mucositis (29%), lymphopenia (26%), neutropenia and anaemia (20% each). CONCLUSIONS: While single-agent selumetinib has no significant activity in STS, the combination may be active for leiomyosarcomas. Nature Publishing Group 2015-05-12 2015-04-21 /pmc/articles/PMC4430716/ /pubmed/25897676 http://dx.doi.org/10.1038/bjc.2015.126 Text en Copyright © 2015 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ |
spellingShingle | Clinical Study Eroglu, Z Tawbi, H A Hu, J Guan, M Frankel, P H Ruel, N H Wilczynski, S Christensen, S Gandara, D R Chow, W A A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas |
title | A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas |
title_full | A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas |
title_fullStr | A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas |
title_full_unstemmed | A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas |
title_short | A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas |
title_sort | randomised phase ii trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430716/ https://www.ncbi.nlm.nih.gov/pubmed/25897676 http://dx.doi.org/10.1038/bjc.2015.126 |
work_keys_str_mv | AT erogluz arandomisedphaseiitrialofselumetinibvsselumetinibplustemsirolimusforsofttissuesarcomas AT tawbiha arandomisedphaseiitrialofselumetinibvsselumetinibplustemsirolimusforsofttissuesarcomas AT huj arandomisedphaseiitrialofselumetinibvsselumetinibplustemsirolimusforsofttissuesarcomas AT guanm arandomisedphaseiitrialofselumetinibvsselumetinibplustemsirolimusforsofttissuesarcomas AT frankelph arandomisedphaseiitrialofselumetinibvsselumetinibplustemsirolimusforsofttissuesarcomas AT ruelnh arandomisedphaseiitrialofselumetinibvsselumetinibplustemsirolimusforsofttissuesarcomas AT wilczynskis arandomisedphaseiitrialofselumetinibvsselumetinibplustemsirolimusforsofttissuesarcomas AT christensens arandomisedphaseiitrialofselumetinibvsselumetinibplustemsirolimusforsofttissuesarcomas AT gandaradr arandomisedphaseiitrialofselumetinibvsselumetinibplustemsirolimusforsofttissuesarcomas AT chowwa arandomisedphaseiitrialofselumetinibvsselumetinibplustemsirolimusforsofttissuesarcomas AT erogluz randomisedphaseiitrialofselumetinibvsselumetinibplustemsirolimusforsofttissuesarcomas AT tawbiha randomisedphaseiitrialofselumetinibvsselumetinibplustemsirolimusforsofttissuesarcomas AT huj randomisedphaseiitrialofselumetinibvsselumetinibplustemsirolimusforsofttissuesarcomas AT guanm randomisedphaseiitrialofselumetinibvsselumetinibplustemsirolimusforsofttissuesarcomas AT frankelph randomisedphaseiitrialofselumetinibvsselumetinibplustemsirolimusforsofttissuesarcomas AT ruelnh randomisedphaseiitrialofselumetinibvsselumetinibplustemsirolimusforsofttissuesarcomas AT wilczynskis randomisedphaseiitrialofselumetinibvsselumetinibplustemsirolimusforsofttissuesarcomas AT christensens randomisedphaseiitrialofselumetinibvsselumetinibplustemsirolimusforsofttissuesarcomas AT gandaradr randomisedphaseiitrialofselumetinibvsselumetinibplustemsirolimusforsofttissuesarcomas AT chowwa randomisedphaseiitrialofselumetinibvsselumetinibplustemsirolimusforsofttissuesarcomas |